Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:cyclin-dependent_kinase_inhibitor |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EF03
|
| gptkbp:brand |
gptkb:Verzenio
|
| gptkbp:CASNumber |
1231929-97-7
|
| gptkbp:chemicalFormula |
C27H32F2N8
|
| gptkbp:combines |
gptkb:fulvestrant
aromatase inhibitors |
| gptkbp:developer |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:eliminationHalfLife |
18 hours
|
| gptkbp:indication |
HER2-negative breast cancer
hormone receptor-positive breast cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
CDK4/6 inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
506.6 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:proteinBinding |
96.3%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea abdominal pain fatigue infections neutropenia |
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:Verzenio
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
abemaciclib
|